FDA accepts Cogent’s bezuclastinib NDA in nonadvanced SM
Cogent’s bezuclastinib cleared FDA filing review in NonAdvSM, with a decision due December 30, 2026.
AI-curated intelligence on the research, legislation, and recalls shaping veterinary medicine. Trusted by veterinary professionals.
Cogent’s bezuclastinib cleared FDA filing review in NonAdvSM, with a decision due December 30, 2026.
Japan cleared Dupixent for bullous pemphigoid, expanding the first targeted option for this rare autoimmune skin disease.
FDA granted Breakthrough Therapy designation to Sanofi’s venglustat for neurological manifestations of type 3 Gaucher disease.
A new Cambridge study suggests BOAS risk extends beyond the usual brachycephalic breeds, with weight and nostril shape also affecting risk.
Daytona Beach nonprofit aims to complete 900 male cat neuters by June 30 through a five-cent campaign.
Veterinary guidance is reinforcing that naloxone can reverse opioid overdose in dogs, but follow-up emergency care is still essential.
AVMA spotlighted rapid glass bead reprocessing, but current guidance warns against quick clinical sterilization use.
Texas A&M and a new case report spotlight overlooked metal exposures and a possible new zinc toxicosis complication in dogs.
ASPCA and PetMD resources show how toxin risks shift by season, giving clinics a roadmap for prevention and triage.
A new meta-analysis underscores PRRSV's global reach and the continuing surveillance burden for swine veterinarians.
A Maryland horse with EHV-1 was euthanized, with 29 others exposed at an Anne Arundel County boarding facility.
Nearly half of imported dogs in an Ontario study had low rabies titres, raising questions about vaccine records and import safeguards.
New equine wound education emphasizes matching topical therapy to wound type, location, and healing stage.
Experts warn that careless antiviral use in cats could threaten the drugs changing FIP outcomes.
FDA’s first generic omeprazole paste could improve access, but diagnosis and disease subtype still drive treatment.
CATalyst Council says cats now make up 24.7% of U.S. vet visits, with a $34 billion feline market opportunity still largely uncaptured.
New pet industry deals are clustering around nutrition, supplements, manufacturing, and animal health infrastructure.
New data shows fewer veterinary visits, higher prices, and growing pressure on preventive care.